1480-66-6

Usage

Uses

Used in Pharmaceutical Industry:
6-chloro-2-(trifluoromethyl)pyrimidin-4-amine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of bioactive molecules. Its unique structural features allow for the creation of compounds with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 6-chloro-2-(trifluoromethyl)pyrimidin-4-amine is utilized as a building block in the production of compounds that can have pesticidal or herbicidal properties, leveraging its reactivity to form new molecules with desired agricultural applications.
Used in Organic Synthesis:
6-chloro-2-(trifluoromethyl)pyrimidin-4-amine is employed as a versatile reactant in organic synthesis, where it can be used to construct a variety of complex organic molecules for different applications, including but not limited to materials science, dyes, and other specialty chemicals.

InChI:InChI=1/C5H3ClF3N3/c6-2-1-3(10)12-4(11-2)5(7,8)9/h1H,(H2,10,11,12)

Upstream product

• 705-24-8 4,6-dichloro-2-(trifluoromethyl)pyrimidine 

Downstream Products

• 943006-41-5 (6-chloro-2-trifluoromethyl-pyrimidin-4-yl)-[5-(3-ethoxy-benzenesulfonyl)-thiazol-2-yl]-amine 

Relevant academic research and scientific papers

PqsR INVERSE AGONISTS

The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.